Explain this page
Arphra AIPlain-English read on Insulet Corporation’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Peers
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.20% | +2.87% | -15.37% | -39.93% | -52.34% | -47.89% | -54.42% | -45.64% | -43.99% | +384.88% | +828.13% |
Aftermarket
LiveLast trade
$145.62
30 sh
Bid
$142.00
10 sh
Ask
$149.50
1 sh
Spread
$7.500
Sector & industry today
LiveSectors
- Technology+0.67%
- Basic Materials+0.15%
- Communication Services+0.13%
- Real Estate-0.13%
- Industrials-0.48%
- Energy-0.58%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.85%
- Consumer Cyclical-0.85%
- Utilities-1.15%
Top industries (issuer's industry highlighted)
- Medical - Devices-0.34%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Coal+5.76%
- Consulting Services+5.28%
- Medical - Healthcare Information Services+5.23%
- Medical - Diagnostics & Research+4.96%
- REIT - Healthcare Facilities-3.49%
- Broadcasting-3.48%
- Software - Application+3.44%
- Advertising Agencies+3.24%
- Biotechnology+3.22%
Fair value
Football field →Weighted blend
$394.35
+166.22% vs spot
Recommendation
Strong Buy
15 of 16 methods
Method spread
4bull11bear
±5% threshold
Analyst PT consensus: $339.00 (+128.85%)
Total assets
$3.19B
Total debt
$1.05B
Cash & equiv
$716.1M
Operating CF
$569.3M
Free cash flow
$377.7M
Buybacks
-$59.6M
Analyst view
DB · price_targets + analyst_gradesConsensus target
$339.00
+128.85% upside
Low
$220.00
Median
$330.00
High
$435.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Insulet Corporation (PODD) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 13, 2026
- Here's Why Insulet (PODD) is a Strong Growth Stockzacks.com·May 12, 2026
- Insulet Reports First Quarter 2026 Resultsbusinesswire.com·May 06, 2026
- Insulet (PODD) is an Incredible Growth Stock: 3 Reasons Whyzacks.com·May 04, 2026
- Insulet (PODD) Upgraded to Buy: Here's Whyzacks.com·May 04, 2026
- Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetesbusinesswire.com·May 04, 2026
- Insulet Initiates EVOLVE Pivotal Study to Advance Fully Closed-Loop Automated Insulin Delivery System for Type 2 Diabetesbusinesswire.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q4 Dec 2025 | $783.8M | $101.6M | $1.44 |
| Q3 Sep 2025 | $706.3M | $87.6M | $1.24 |
| Q2 Jun 2025 | $649.1M | $22.5M | $0.32 |
| Q1 Mar 2025 | $569M | $35.4M | $0.50 |
| Q4 Dec 2024 | $597.5M | $100.7M | $1.39 |
| Q3 Sep 2024 | $543.9M | $77.5M | $1.08 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
MINOGUE MICHAEL R director | Buy | 2,030 | $499.85K | Feb 25, 2026 |
McEvoy Ashley director, officer: President and CEO | Buy | 4,300 | $1.03M | Feb 20, 2026 |
Frederick Wayne A.I. director | Sell | 1,851 | $542.51K | Dec 15, 2025 |
STONESIFER TIMOTHY C. director | Buy | 962 | $299.88K | Dec 05, 2025 |
Singh Prem officer: SVP, Global Operations | Sell | 687 | $238.73K | Sep 08, 2025 |
Cousin Laetitia officer: SVP, Reg, Quality & Compliance | Sell | 797 | $278K | Sep 08, 2025 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $2.71B | $473.8M | $247.1M | $3.48 | +9.12% |
| FY 2024 | $2.07B | $308.9M | $418.3M | $5.78 | +20.19% |
| FY 2023 | $1.7B | $220M | $206.3M | $2.94 | +12.16% |
| FY 2022 | $1.31B | $37.6M | $4.6M | $0.07 | +0.35% |
| FY 2021 | $1.1B | $126M | $16.8M | $0.25 | +1.53% |